Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/organoid-culture-harvest-timing-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Organoid CultureOrganoid Culture Harvest Timing Patents: Who Holds the Harvest Window
- One assignee leads the ranked field with 11 records against a long tail where the fifth-ranked holder has only 2 and the tenth has 1.
- Filing nearly quadrupled from 2021 to 2024 up 300% across that span, after a 2020 peak of 10 filings in a single year.
- Bioreactor and analytical classes trail genetic-engineering claims C12M bioreactor apparatus sits at 32.4% of the 34 records in scope, and G01N testing at 29.4% — both far behind C12N's 91.2%.
34
Published Records
+300%
Filing Growth 2021→2024
US
Leading Jurisdiction
11
Active Filers Ranked
Filing growth compares 2021 (1 records) with 2024 (4) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Field Overview
What this landscape covers
Harvest timing in organoid culture sits at the junction of cell biology and process engineering: knowing when viability begins to decline, when impurity release starts, or when a quality attribute crosses a threshold determines when a batch is pulled. This landscape tracks 34 published records filed against IPC classes covering microorganism and genetic-engineering culture methods, bioreactor apparatus, and material testing, filtered to documents that explicitly discuss viability decline, product titer, apoptosis markers or harvest windows alongside organoid or organotypic culture.
The scope spans filings from 2015 through the 2026-07-31 cut-off. Because publication lags filing by roughly 18 months, the most recent years understate real filing activity and should be read as provisional rather than a slowdown.
Filing activity and technology composition, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Numbers
Filing trend and technology split
The record set is small enough that individual years move sharply, but the underlying pattern — a 2020 spike followed by renewed growth from 2021 — is consistent across the filing trend and the IPC composition.
Filing trend: a 2020 peak, then a fresh growth phase
Filings sat at zero in 2017, rose to a peak of 10 in 2020, and after a quiet 2021 (1 filing) climbed to 4 by 2024 — a 300% increase over that three-year span. 2025 and 2026 figures will fill in further as publication catches up.
Technology composition: culture method claims dominate
C12N (microorganism and genetic-engineering culture methods) appears in 91.2% of the 34 records in scope, far ahead of C12M bioreactor apparatus (32.4%) and G01N material testing (29.4%). C12Q enzyme/DNA measurement (17.6%) and smaller shares in C07K peptides, A61K medicinal preparations, A01N biocides and C12R microorganism indexing round out the set — each of these smaller classes marks a narrower, less-crowded claim area.
Shares are the percentage of the 34 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Organoid Culture Harvest Timing with Eureka
This page is one run against one query. Ask Eureka your own question about organoid culture harvest timing and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Most-cited records in this dataset
Representative Filing
Highly efficient organoid culture device and system
CELLARTGEN INC.
The present invention provides an organoid culture device, comprising at least one first chamber for storing a culture medium; at least one second chamber for culturing an organoid; and a channel that interconnects adjacent chambers.Filed by Cellartgen Inc., granted as US11725173B2 (2023-08-15), and related to the most-cited record in this set, US20190390149A1.
Highest-citation records
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20190390149A1 | Highly efficient organoid culture device and system | 24 |
| 2 | WO2020247528A1 | Uses of patient-derived intestinal organoids for celiac disease diagnosis, screening and treatment | 12 |
| 3 | WO2020019023A1 | Composition and method | 12 |
| 4 | US20200308550A1 | Tumor organoid model | 6 |
| 5 | WO2021055579A1 | Cell culture media tablets and methods of manufacture | 3 |
| 6 | US20220372435A1 | Cell Culture Media Tablets and Methods of Manufacture | 3 |
| 7 | US20240026268A1 | Microfluidic hanging drop culture device for culturing cell aggregate | 2 |
| 8 | WO2023246838A1 | Disease model and use thereof | 2 |
| 9 | WO2024168086A1 | Room-temperature-stable culture media and supplements | 1 |
| 10 | US20220221445A1 | Uses of patient-derived intestinal organoids for celiac disease diagnosis screening and treatment | 1 |
Citation counts favour older documents in any searched corpus; treat them as a signal of influence within this dataset, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Analysis
What the evidence indicates
Three patterns stand out once the ranking, the trend and the IPC split are read together.
Concentration
11 vs. 2
leader vs. fifth place
A single leader, then a fast drop-off
The ranked leader holds 11 records against a fifth-place holder at 2 and a tenth-place holder at 1. That gap suggests one organisation built a broad filing position early, while most other entrants hold only one or two records — a pattern typical of a field still open to new claim scope rather than one locked down by a handful of incumbents.
Based on the 11-company assignee ranking
Momentum
+300%
2021 → 2024 filings
Renewed filing growth after 2021
Filings dropped to a single record in 2021 after the 2020 peak of 10, then climbed back to 4 by 2024 — a 300% increase over that span. Recent-year momentum data shows most named assignees at zero filings in the latest year, consistent with publication lag rather than an actual pullback.
2024 is the most recent year treated as complete
Technology mix
32.4%
C12M bioreactor share
Apparatus claims trail culture-method claims
Bioreactor and apparatus claims (C12M) cover 32.4% of the 34 records, and material-testing claims (G01N) cover 29.4% — both well behind the 91.2% carrying C12N culture-method claims. That gap between method claims and apparatus or testing claims is where less-crowded filing room tends to sit.
Shares of the 34 records in scope; a record can carry multiple classes
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organoid culture harvest timing, with the prior art for and against each one.
Co-filing is rare
| Assignee | Co-assignee | Shared families |
|---|---|---|
| 4B Tech (Beijing) Co., Ltd. | Tsinghua University | 2 |
| Cedars-Sinai Medical Center | The Regents of the University of California | 1 |
Only 2 co-assignee pairs appear across the dataset, indicating most work here is filed by a single organisation rather than through joint ventures or research partnerships.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Who's Filing
The assignee landscape
The ranking returned by the dataset covers 11 companies and research institutions, counted in records — this is the entire ranking the endpoint returns, not a top-50 or top-100 cut.
Leader
11 records
of 34 in scope
One organisation with broad early coverage
The top-ranked assignee holds 11 of the 34 records in this landscape, well ahead of the rest of the field. Its representative filing, US11725173B2, describes a multi-chamber organoid culture device and is tied to the most-cited record in the dataset.
Assignee ranking, 34 records in scope
Mid-field
2 records
fifth place
A thin mid-tier behind the leader
Fifth place in the ranking holds only 2 records, and tenth place holds 1 — indicating that beyond the leader, most organisations in this space have filed only a small handful of documents each.
Assignee ranking
Geography
12 US, 10 EPO, 7 PCT
top receiving offices
US and Europe lead filing offices
The United States receives the most filings (12), followed by the EPO (10) and WIPO/PCT routes (7), with smaller numbers in India, Australia and Canada. This spread points to a field where applicants are still securing coverage across multiple major jurisdictions rather than concentrating on a single home market.
Receiving office counts across the dataset
Recent-year filing momentum
| Assignee | Recent year | YoY |
|---|---|---|
| Life Technologies Corporation | 1 | 0% |
| The Board of Trustees of the Leland Stanford Junior University | 0 | — |
| CELLARTGEN INC | 0 | — |
| The Kitasato Institute | 0 | — |
| 4B Tech (Beijing) Co., Ltd. | 0 | — |
| Tsinghua University | 0 | — |
| Yonsei University Industry Foundation | 0 | — |
| Murdoch Children's Research Institute | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Next Steps
Where to take this
The trend and composition data point to a field with an established leader but plenty of unclaimed apparatus and testing territory.
Check freedom-to-operate around harvest-window claims
Before designing a device or assay tied to viability decline or apoptosis markers, review the leader's filings and the most-cited records to see how broadly the culture-method claims are drawn.
Explore claims in EurekaWatch the bioreactor and testing classes
C12M and G01N carry lower record shares than C12N, suggesting apparatus and analytical claim space is less occupied and worth monitoring for new entrants.
Track filings in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on this landscape
One assignee leads the ranked field with 11 of the 34 records in scope, well ahead of the rest of the ranking. The fifth-ranked holder has only 2 records and the tenth has 1, showing a sharp drop-off after the leader. This pattern suggests the field has one organisation with broad early coverage and a long tail of smaller filers rather than several evenly matched competitors.
Filings peaked at 10 in 2020, dropped to 1 in 2021, and then grew back to 4 by 2024 — a 300% increase over that three-year span. 2025 and later figures will rise further as publication catches up, since publication typically lags actual filing by around 18 months. Based on the complete years available, the trend through 2024 points to renewed growth rather than a decline.
Most records (91.2% of the 34 in scope) carry IPC class C12N, covering microorganism and genetic-engineering culture methods. Bioreactor and apparatus claims (C12M) appear in 32.4% of records, and material-testing claims (G01N) in 29.4%, with smaller shares in enzyme/DNA measurement, peptides, medicinal preparations and biocide-related classes. Because a single record can carry multiple IPC classes, these shares add up to more than 100%.
US11725173B2, assigned to Cellartgen Inc. and granted in August 2023, describes an organoid culture device with at least one chamber for storing culture medium, at least one chamber for culturing the organoid, and a channel interconnecting adjacent chambers. It is closely related to US20190390149A1, the most-cited record in this dataset. Anyone building a multi-chamber organoid culture device should review this claim structure closely, since it covers a fairly foundational chamber-and-channel configuration.
The lower-share IPC classes point to the open areas: apparatus and bioreactor design (C12M, 32.4% of records), material testing tied to quality attributes (G01N, 29.4%), and smaller categories like peptide-based media supplementation and enzyme/DNA-based testing (C07K and C12Q). These branches carry far fewer records than the dominant culture-method class (C12N, 91.2%), suggesting narrower but still available claim territory for a first-mover filing there.
Answers are grounded in the same dataset. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Organoid Culture Harvest Timing in depth with Eureka
Go past this page: query the whole organoid culture harvest timing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.